Hypothermia, Immunology
In this video, Oscar Streeter Jr. spends about 23 minutes speaking on "Hypothermia, Immunology" at the 43rd Annual Cancer Convention held on Labor Day weekend by the Cancer Control Society.
About Oscar Streeter Jr.
OSCAR STREETER, JR., M.D., F.A.C.R.O. is a Board Certified Radiation Oncologist and Certified Medical Acupuncturist. Dr. Streeter attended Medical School and completed his residency at Howard University, and spent 18 years at the Keck School of Medicine at the University of Southern California holding positions as Associate Professor, Residency Program Director and Chief of the Radiation Oncology Department for several years at LAC+USC Medical Center and Chief of Service in Radiation Oncology at USC/Norris Cancer Hospital.
In 2008, Dr. Streeter became the Chair of Radiation Oncology and Professor at Howard University, in Washington, D.C., where he successfully revived their program. In 2012, he was recruited to be the Founding Medical Director of the AIS Cancer Center at San Joaquin Community Hospital where he implemented state-of-art technologies and was instrumental in having UC Davis Cancer Center Network to choose his Center for their program.
Dr. Streeter is currently serving on the voting board of the California Division of the American Cancer Society and is a Fellow of the American College of Radiation Oncology. Since 2003, Dr. Streeter has been listed on the prestigious U.S. News & World Report, “Best Doctors in America.”
During his 18 year tenure at USC, Dr. Streeter recognized the significant value of Hyperthermia in the treatment of cancer, and prescribed Hyperthermia Treatments at what was, at that time, the only academic facility delivering this important modality in Southern California. Dr. Streeter is a published expert in both superficial and deep Hyperthermia Treatment combined with Chemotherapy and Radiation Therapy, and currently serves as Medical Director at the Center For Thermal Oncology in Santa Monica where he combines Hyperthermia Treatment with state-of-the-art radiation therapy, integrative and immunotherapies and traditional and Fractionated Chemotherapy regimens. The Center for Thermal Oncology, under his leadership, has become the preeminent Hyperthermia Treatment Center in the United States and possibly the world.
Dr. Streeter may be contacted at the Center for Thermal Oncology by phone 888-580-5900, fax 877-400-8093, and website www.thermaloncology.com
Transcription
One of the important things to say before I get started is not only at UCSF. They've been very important in helping establish hypothermia. One of their graduates is now, as the Cleveland Clinic, doing quite good work and also at Thomas Jefferson. They and Duke, they've done a lot of the publications.
Made a difference. Accepted hypothermia in this community and try to stay on time here. And I'll start my clock, speak for 25 minutes. And then one of the things is society asked if we have a patient, we have a patient who who's going to speak at the last five minutes. And I introduce him then.
OK, so we're gonna get started.
So hypothermia basically is our hypothermia. How we use is produced by ultrasound is FDA approved, which is very important in terms of those you have insurance that will be reimbursed that way. It's nontoxic, has no long term side effects. And we use a machine called the Sun, a thermal 1000 cenotes for sound technology can treat deep or superficial tumors for s.m, deep or even up to 12 ACMD. And you'll see cases where we've treated deeply for these tumors, hypothermia or thermal therapy. We started temperature 37 degrees centigrade and we slowly raise it up 38, 40 degrees, 41, 42 or 110 degrees Fahrenheit is similar to a high fever, but it's actually called in a literature's mild hypothermia versus high flu, which is high intensity frequency ultrasound, which is ablation therapies at 60 degrees centigrade, which you can only give about once in the clinic and also has significant tuque toxicity. So the efficacy of local and external hypothermia is, as Frank is, as you said it was, it's been proven in more than 3500 clinical trials. It's been peer reviewed. It's been randomized in some of the best journals, Lancet Oncology. It's been multicenter. It's been prospective. It means that instead of looking back at it, you actually get all the data front and get the results you get. And that's what you live with. So hypothermia has been treated for soft tissue sarcomas and bones are comas. We're in the process of writing a new combined trial. Large breast cancers as neoadjuvant therapy, head neck cancers not behind bone base of tongue cancers, advanced cervical cancer. It's actually the standard of care, advanced cervical cancer or hypothermia. And R in in Amsterdam now is the standard of care, chest wall recurrences, large axillary lymph nodes or residual after surgery, advanced laryngeal cancers, thyroid cancers are not resectable or surgical residual rectal cancer and anal cancer. It also works as well. Combined with our T and chemotherapy, advanced prostate